how big is Anuh Pharma?

As of Jun 06, Anuh Pharma Ltd has a market capitalization of 1,057.11 Cr, with recent net sales of 138.83 Cr and no net profit reported for the latest two quarters. Shareholder's funds are valued at 291.22 Cr, and total assets amount to 445.26 Cr.

Market Cap: As of Jun 06, Anuh Pharma Ltd has a market capitalization of 1,057.11 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest two quarters, the sum of Net Sales is 138.83 Cr, and the sum of Net Profit is 0.00 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. Shareholder's Funds are valued at 291.22 Cr, and Total Assets amount to 445.26 Cr.

Who are in the management team of Anuh Pharma?

As of March 2023, the management team of Anuh Pharma includes Bipin N Shah (Vice Chairman), Jasvantlal Shah (Chairman & Independent Director), and several other directors and joint managing directors, totaling 15 members with diverse roles in governance and management.

As of March 2023, the management team of Anuh Pharma includes the following individuals:<BR><BR>1. Bipin N Shah - Vice Chairman<BR>2. Bharat N Shah - Non-Executive & Non-Independent Director<BR>3. Arun L Todarwal - Non-Executive & Independent Director<BR>4. Samir J Shah - Non-Executive & Non-Independent Director<BR>5. Ketan L Shah - Non-Executive & Non-Independent Director<BR>6. Ritesh B Shah - Joint Managing Director<BR>7. Vivek B Shah - Joint Managing Director<BR>8. Jasvantlal Shah - Chairman & Independent Director<BR>9. Mita Dixit - Non-Executive & Non-Independent Director<BR>10. Harmanbhai Tulsibhai Patel - Non-Executive & Independent Director<BR>11. Sandeep M Joshi - Non-Executive & Independent Director<BR>12. Hemant Auti - Company Secretary & Compliance Officer<BR>13. Pradeep Thakur - Independent Director<BR>14. Siddharth Shah - Independent Director<BR>15. Gaurav Shah - Independent Director<BR><BR>This diverse team includes various roles such as directors, joint managing directors, and a compliance officer, contributing to the governance and management of the company.

When is the next results date for Anuh Pharma?

No Upcoming Board Meetings

Has Anuh Pharma declared dividend?

Anuh Pharma Ltd has declared a 50% dividend, amounting to ₹2.5 per share, with an ex-date of August 16, 2024. While recent performance shows declines in the short term, the company has delivered positive total returns over longer periods, particularly in the 2 and 3-year spans.

Anuh Pharma Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 2.5<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 1.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.38%, with no dividend return, resulting in a total return of -4.38%.<BR><BR>Over the past year, the price return was -4.35%, with a dividend return of 1.08%, leading to a total return of -3.27%.<BR><BR>In the 2-year period, the price return was 136.42%, with a dividend return of 4.02%, resulting in a total return of 140.44%.<BR><BR>For the 3-year period, the price return was 127.47%, with a dividend return of 7.41%, culminating in a total return of 134.88%.<BR><BR>In the last 4 years, the price return was 57.33%, with a dividend return of 5.62%, leading to a total return of 62.95%.<BR><BR>Over the 5-year period, the price return was 110.42%, with a dividend return of 7.11%, resulting in a total return of 117.53%.<BR><BR>Overall, Anuh Pharma has declared a dividend, contributing positively to returns over longer periods, particularly in the 2 and 3-year spans, while recent performance shows a decline in the shorter term.

Is Anuh Pharma overvalued or undervalued?

As of April 8, 2025, Anuh Pharma's valuation has shifted to attractive, with a PE ratio of 22.36, an EV to EBITDA of 16.77, and a ROCE of 23.53%, indicating it is fairly valued compared to peers despite a recent 1-year return of -4.51% against the Sensex's 7.60%.

As of 8 April 2025, Anuh Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived investment quality. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 22.36, an EV to EBITDA of 16.77, and a ROCE of 23.53%. <BR><BR>In comparison to its peers, Anuh Pharma's PE ratio is in line with the industry average, while its EV to EBITDA is also competitive. Notable peers include a company with a PE of 22.5 and another with an EV to EBITDA of 17.0. Despite recent underperformance against the Sensex, with a 1-year return of -4.51% compared to the Sensex's 7.60%, the company's strong fundamentals suggest it is positioned well within the pharmaceuticals and biotechnology sector.

What is the bonus history of Anuh Pharma?

Anuh Pharma has a history of issuing bonus shares, including a recent 1:1 bonus announced for July 15, 2025, and previous bonuses of 1:1 in September 2020, 2:1 in August 2015, 2:1 in October 2010, and 1:1 in August 2006. This reflects the company's commitment to rewarding shareholders.

Anuh Pharma has a notable history of bonus issues. Here’s a summary of their bonus announcements:<BR><BR>1. **Latest Bonus**: A 1:1 bonus issue was announced, with an ex-date of July 15, 2025.<BR> <BR>2. **Previous Bonuses**:<BR> - On September 21, 2020, a 1:1 bonus was issued, with the ex-date on September 18, 2020.<BR> - On August 6, 2015, the company issued a 2:1 bonus, with the ex-date on August 5, 2015.<BR> - On October 29, 2010, another 2:1 bonus was issued, with the ex-date on October 28, 2010.<BR> - The earliest in this history was a 1:1 bonus on August 7, 2006, with the ex-date on July 31, 2006.<BR><BR>This history reflects Anuh Pharma's approach to rewarding its shareholders through bonus shares over the years.

Who are the peers of the Anuh Pharma?

Anuh Pharma's peers include IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, SMS Pharma, Amrutanjan Health, Windlas Biotech, Syncom Formulations, and Jagsonpal Pharma. In terms of performance, Panacea Biotec leads with a 1-year return of 215.30%, while Anuh Pharma has a return of -9.06%.

Peers: The peers of Anuh Pharma are IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, SMS Pharma., Amrutanjan Healt, Windlas Biotech, Syncom Formul., Jagsonpal Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India, Amrutanjan Healt, and Windlas Biotech, while Average management risk is found at IOL Chemicals, SMS Pharma., Syncom Formul., and Jagsonpal Pharma, and the rest. Below Average management risk is present at Panacea Biotec and Solara Active. In terms of growth, Good growth is seen at Novartis India and Jagsonpal Pharma, Average growth is found at Anuh Pharma, while Below Average growth is noted for IOL Chemicals, Panacea Biotec, Solara Active, SMS Pharma., and the rest. Excellent capital structure is held by IOL Chemicals, Novartis India, Amrutanjan Healt, Windlas Biotech, Syncom Formul., and Jagsonpal Pharma, while Average capital structure is noted for SMS Pharma., and Below Average for Panacea Biotec and Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while Anuh Pharma has a 1-year return of -9.06%, indicating a significantly lower performance compared to its peers. The peer with the lowest 1-year return is Novartis India at -9.48%. Additionally, Windlas Biotech and Amrutanjan Healt have negative six-month returns.

What does Anuh Pharma do?

Anuh Pharma Ltd is a small-cap manufacturer of Active Pharmaceutical Ingredients (APIs) in the Pharmaceuticals & Biotechnology industry, with recent net sales of ₹1,981 Cr and a net profit of ₹125 Cr as of March 2025. The company has a market cap of ₹1,035 Cr and key metrics include a P/E ratio of 22.00 and a dividend yield of 1.18%.

Overview: <BR>Anuh Pharma Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History: <BR>Anuh Pharma Ltd was incorporated on February 19, 1960. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,981 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 125 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 1,035 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.18% <BR>Debt-Equity: -0.12 <BR>Return on Equity: 15.62% <BR>Price to Book: 3.51 <BR><BR>Contact Details: <BR>Address: 3-A Shivsagar Estate, North Wing Dr A B Road Worli Mumbai Maharashtra : 400018 <BR>Tel: 91-22-6622 7575 <BR>Email: anuh@sk1932.com <BR>Website: http://www.anuhpharma.com

Who are the top shareholders of the Anuh Pharma?

The top shareholders of Anuh Pharma are primarily its promoters, with Bharti Bipin Shah holding the largest stake at 19.43%. Individual investors own 25.92% of the shares, while foreign institutional investors hold a minimal 0.04%, and there are no pledged promoter holdings.

The top shareholders of Anuh Pharma primarily consist of its promoters, with Bharti Bipin Shah being the individual with the highest holding at 19.43%. Additionally, individual investors collectively hold 25.92% of the company's shares. There are no mutual funds involved, and foreign institutional investors (FIIs) hold a minimal stake of 0.04% through three different entities. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Are Anuh Pharma latest results good or bad?

Anuh Pharma's latest results are concerning, showing a 22.54% increase in net sales but a 35.19% decline in net profit, leading to a downgrade in outlook to "Mildly Bearish." The significant drop in profitability and shrinking margins indicate operational challenges that the company must address.

Anuh Pharma's latest results indicate a challenging situation for the company. While net sales for the first half of FY2026 grew by a robust 22.54% to ₹372.36 crores, the net profit saw a significant decline of 35.19%, falling to just ₹15.91 crores. This stark contrast between revenue growth and profit decline raises concerns about the company's operational efficiency and margin sustainability.<BR><BR>The overall profitability metrics have deteriorated, with operating margins contracting from 11.6% in FY2024 to 9.2% in FY2025. Additionally, the net profit for FY2025 was down 21.67% compared to the previous year. Such profit compression has led to a downgrade in the company's outlook to "Mildly Bearish," reflecting institutional concerns regarding its ability to maintain margins in a competitive environment.<BR><BR>In summary, despite the positive revenue growth, the significant drop in profitability and ongoing margin pressures suggest that the latest results are more negative than positive for Anuh Pharma. The company faces critical operational challenges that need to be addressed to restore investor confidence and improve financial performance moving forward.

How has been the historical performance of Anuh Pharma?

Anuh Pharma has shown consistent growth in net sales, increasing from 306.96 Cr in Mar'20 to 661.51 Cr in Mar'25, despite recent declines in profitability metrics. Total assets also grew significantly, while cash flow from operating activities improved notably in the same period.

Answer:<BR>The historical performance of Anuh Pharma shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Anuh Pharma's net sales have steadily increased from 306.96 Cr in Mar'20 to 661.51 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 306.96 Cr in Mar'20 to 661.51 Cr in Mar'25. The raw material cost peaked at 489.73 Cr in Mar'24 but decreased to 463.28 Cr in Mar'25, indicating improved cost management. Operating profit (PBDIT) saw fluctuations, peaking at 87.24 Cr in Mar'24 before dropping to 70.36 Cr in Mar'25. Profit before tax also experienced a decline from 78.31 Cr in Mar'24 to 61.01 Cr in Mar'25, while profit after tax decreased from 60.06 Cr to 47.35 Cr in the same period. The company's total assets grew from 326.37 Cr in Mar'20 to 504.55 Cr in Mar'25, with total liabilities increasing from 326.37 Cr to 504.55 Cr as well. Cash flow from operating activities improved significantly from 12.00 Cr in Mar'24 to 37.00 Cr in Mar'25, contributing to a net cash inflow of 12.00 Cr in Mar'25, up from 5.00 Cr in Mar'24. Overall, Anuh Pharma's financials indicate a robust growth trajectory, despite some recent declines in profitability metrics.

Should I buy, sell or hold Anuh Pharma?

Is Anuh Pharma technically bullish or bearish?

As of December 2, 2025, Anuh Pharma's trend has shifted to a bearish stance with moderate strength, driven by bearish MACD and moving averages, alongside mixed signals from Bollinger Bands and KST, indicating a negative outlook for the stock.

As of 2 December 2025, the technical trend for Anuh Pharma has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and mildly bearish signals from Bollinger Bands on both weekly and monthly charts. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating mixed signals in the short term. Overall, the lack of strong bullish momentum and the prevailing bearish indicators suggest a negative outlook for the stock.

Which are the latest news on Anuh Pharma?

Why is Anuh Pharma falling/rising?

As of 04-Dec, Anuh Pharma Ltd's stock price is at 79.20, down 0.8%, and has underperformed the sector today. Despite a recent weekly gain of 3.19%, the stock has a year-to-date decline of 29.83%, indicating significant long-term challenges and reduced investor interest.

As of 04-Dec, Anuh Pharma Ltd's stock price is currently at 79.20, reflecting a decrease of 0.64, or 0.8%. The stock has underperformed compared to the sector today by 1.09%. Over the past week, the stock has shown a positive return of 3.19%, while the benchmark Sensex has declined by 0.53%. However, the stock's performance over the longer term indicates significant challenges, with a year-to-date decline of 29.83% compared to a 9.12% increase in the Sensex.<BR><BR>Additionally, the stock's moving averages indicate that it is currently higher than its 5-day moving average but lower than its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a potential downward trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 66.71% against the 5-day average, indicating reduced interest from investors. This combination of underperformance relative to the sector, declining investor participation, and unfavorable long-term performance metrics contributes to the stock's current downward movement.